Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,024 active trials9 approved drugs78 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05980000 | Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma(Rambro2) | active not recruiting | Phase 2 | 37 | Washington University School of MedicineOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03410615 | Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC | active not recruiting | Phase 2 | 129 | Canadian Cancer Trials Group |
| 4 |
| Mar 24, 2026 |
| clinicaltrials |
| NCT06332092 | FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma(HNSCC) | active not recruiting | Phase 2 | 46 | Fulgent Pharma LLC.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT04030455 | Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer | active not recruiting | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT03174275 | Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 2 | 39 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04150900 | 1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck | active not recruiting | Phase 2 | 7 | University of Maryland, BaltimoreOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT04868877 | Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | active not recruiting | Phase 1 / Phase 2 | 194 | Merus B.V.INDUSTRY | 9 | Feb 19, 2026 | clinicaltrials |
| NCT05286060 | Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer(GENUINE) | active not recruiting | Phase 2 | 56 | Yonsei UniversityOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | active not recruiting | Phase 1 / Phase 2 | 143 | TransgeneINDUSTRY | 3 | Feb 5, 2026 | clinicaltrials |
| NCT05737199 | Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma | active not recruiting | Phase 2 | 21 | Niigata University Medical & Dental HospitalOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05621707 | Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)(RICE) | active not recruiting | Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT03474497 | UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | active not recruiting | Phase 1 / Phase 2 | 18 | Megan Daly, MDOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT02769520 | Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck | active not recruiting | Phase 2 | 27 | Assuntina G. Sacco, MDOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05366166 | Pembrolizumab Plus Olaparib in LA-HNSCC | active not recruiting | Phase 2 | 45 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03468218 | Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer | active not recruiting | Phase 2 | 36 | Emory UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT03546582 | SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma(KEYSTROKE) | active not recruiting | Phase 2 | 86 | RTOG Foundation, Inc.OTHER | 2 | Jan 20, 2026 | clinicaltrials |
| NCT04183166 | A Clinical Trial Evaluating TG4050 in Head and Neck Cancer | active not recruiting | Phase 1 / Phase 2 | 80 | TransgeneINDUSTRY | 4 | Jan 16, 2026 | clinicaltrials |
| NCT05312710 | Safety and Efficacy of APG-157 in Head and Neck Cancer | active not recruiting | Phase 2 | 24 | Aveta Biomics, Inc.INDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04229459 | Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients. | active not recruiting | Phase 2 | 12 | Baruch BrennerOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06115499 | The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | active not recruiting | Phase 2 / Phase 3 | 10 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04141449 | A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation(Potlako+) | active not recruiting | Phase 2 | 874 | Brigham and Women's HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05858229 | Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1. | active not recruiting | Phase 1 / Phase 2 | 12 | Sherrif IbrahimOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05120271 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors(DUET-1) | active not recruiting | Phase 1 / Phase 2 | 7 | Sotio Biotech Inc.INDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
| NCT07267286 | Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma (HNC-SYSU-005) | active not recruiting | Phase 2 | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05433116 | Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC | active not recruiting | Phase 2 | 50 | Universität des SaarlandesOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05659251 | Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 48 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05189730 | Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC(ETNT) | active not recruiting | Phase 2 | 80 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04074967 | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | active not recruiting | Phase 1 / Phase 2 | 70 | Dan ZandbergOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT04643379 | Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | active not recruiting | Phase 2 | 30 | Washington University School of MedicineOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT03383094 | Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer | active not recruiting | Phase 2 | 126 | Loren Mell, MDOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT05022654 | SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma. | active not recruiting | Phase 2 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05044897 | A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC | active not recruiting | Phase 2 | 11 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT06247956 | Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer | active not recruiting | Phase 2 | 153 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT03070366 | Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC(OMET) | active not recruiting | Phase 2 | 78 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT07142421 | A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 35 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT06082167 | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(STELLAR-305) | active not recruiting | Phase 2 / Phase 3 | 600 | ExelixisINDUSTRY | 26 | Aug 17, 2025 | clinicaltrials |
| NCT04675333 | Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) | active not recruiting | Phase 2 | 172 | ALX Oncology Inc.INDUSTRY | 8 | Aug 3, 2025 | clinicaltrials |
| NCT04675294 | Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) | active not recruiting | Phase 2 | 189 | ALX Oncology Inc.INDUSTRY | 9 | Aug 1, 2025 | clinicaltrials |
| NCT05286294 | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders(MITRIC) | active not recruiting | Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT02817958 | Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis(MEGACEP) | active not recruiting | Phase 2 | 37 | UNICANCEROTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04305795 | An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 23 | Rakuten Medical, Inc.INDUSTRY | 1 | Jun 19, 2025 | clinicaltrials |
| NCT03341936 | Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN | active not recruiting | Phase 2 | 29 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT04946968 | Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers | active not recruiting | Phase 2 | 24 | National Cancer Centre, SingaporeOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT03854032 | Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck | active not recruiting | Phase 2 | 45 | Thomas Jefferson UniversityOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06009861 | Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT) | active not recruiting | Phase 2 | 110 | Peking University Hospital of StomatologyOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT05555862 | Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL(anal HSIL HIV-) | active not recruiting | Phase 2 | 17 | Frantz Viral Therapeutics, LLCINDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT04666090 | Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 42 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 15, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 31, 2026source: clinicaltrials